correct
balanc
immun
effector
regulatori
respons
depend
number
molecular
interact
antigenpres
cell
apc
tcell
key
interact
immunolog
toler
receptor
program
deathligand
program
apc
express
lead
bind
molecul
tcell
result
activ
tyrosin
phosphatas
dephosphoryl
critic
kinas
involv
tcell
receptor
tcr
signal
blockad
interact
diminish
treg
enhanc
effector
cell
increas
cytokin
product
vitro
interact
thu
target
immunolog
situat
featur
restrict
antigen
present
tcell
anergi
immun
toler
detriment
characterist
name
chronic
infecti
diseas
malign
latter
scenario
clinic
trial
demonstr
remark
efficaci
drug
develop
target
receptor
clinic
respons
rate
refractori
worldwid
tuberculosi
tb
lead
caus
death
due
infecti
diseas
vaccin
avail
bacillu
bcg
show
modest
protect
adult
alarmingli
low
efficaci
develop
countri
tb
mortal
highest
bcg
like
pathogen
rel
tuberculosi
imped
antigen
present
believ
contribut
rel
low
efficaci
vaccin
human
mycobacteriainduc
express
postul
major
mechan
drive
impair
antigen
current
fulli
understood
molecular
mechan
underpin
bcgmediat
upregul
ii
immunolog
consequ
block
pathway
bcg
immunis
year
bcg
employ
frontlin
immunotherapi
bladder
use
sinc
late
malign
although
mechan
action
remain
complet
elucid
believ
bacteria
trigger
inflammatori
respons
lead
immun
cell
infiltr
tumour
site
thu
facilit
immunemedi
like
mediat
innat
ie
tolllik
receptor
signal
provid
scope
improv
concomit
engag
adapt
immun
respons
known
suppress
show
first
time
bcg
induc
upregul
macrophag
dendrit
cell
dc
via
autocrineparacrin
secret
cytokin
chiefli
blockad
receptor
vivo
bcg
immunis
led
superior
tcell
respons
recal
antigen
thu
highlight
potenti
util
pathway
clinic
set
find
provid
new
target
improv
bcg
tb
vaccin
cancer
immunotherapi
experi
involv
live
anim
full
ethic
approv
st
georg
univers
ethic
committe
uk
home
offic
project
licens
accord
anim
scientif
procedur
act
bcg
strain
pasteur
kind
gift
professor
juraj
ivanyi
king
colleg
london
grown
accord
previou
use
standard
microbiolog
techniqu
bcg
express
green
fluoresc
protein
gfp
also
ivanyi
laboratori
grown
ident
condit
select
media
agar
contain
hygromycin
b
sigmaaldrich
femal
mice
week
old
obtain
charl
river
laboratori
uk
mice
administ
mg
antibodi
rat
isotyp
control
kind
gift
professor
ann
cook
univers
cambridg
via
intraperiton
ip
rout
day
twentyfour
hour
later
day
mice
receiv
cfu
bcg
subcutan
sc
mice
receiv
booster
immunis
mg
per
dose
day
confirm
receptor
blockad
mice
administ
mg
via
ip
rout
follow
euthanasia
h
immedi
ex
vivo
stain
splenocyt
cell
stain
report
compet
fluorochromeconjug
clone
bind
epitop
test
success
receptor
blockad
fig
addit
control
specif
also
stain
treatment
bone
marrowderiv
dc
obtain
previous
cell
flow
cytometri
dc
stimul
complet
rpmi
contain
fc
lglutamin
uml
penicillinstreptomycin
sigmaaldrich
experi
involv
macrophag
cell
line
use
cell
grown
stimul
complet
dmem
recip
rpmi
sigmaaldrich
bcg
infect
bacteria
wash
complet
media
without
antibiot
apc
inocul
design
moi
cell
cultur
humidifi
incub
experi
e
colideriv
lipopolysaccharid
lp
sigmaaldrich
use
ngml
cytokin
peprotech
uk
dilut
complet
rpmi
administr
interleukin
block
antibodi
purchas
biolegend
uk
precultur
cell
h
stimul
stattic
tocri
bioscienc
uk
dilut
dmso
sigmaaldrich
cell
treat
h
infect
spleen
asept
remov
euthanis
mice
mechan
homogenis
treat
ack
lysi
buffer
cell
count
seed
per
well
complet
rpmi
follow
treatment
brefeldin
sigmaaldrich
cell
stimul
lionex
germani
ppd
nibsc
uk
biolegend
hour
stain
flow
cytometri
pmaionomycin
treatment
ngml
respect
sigmaaldrich
use
posit
control
stain
boundari
data
shown
lymph
node
analysi
inguin
lymph
node
excis
euthanis
mice
indic
day
follow
mechan
disrupt
count
immedi
flow
cytometr
analysi
experi
cell
first
wash
pb
incub
viabil
dye
fixabl
viabil
dye
ebiosci
fc
receptor
blockad
trustain
biolegend
minut
cell
wash
flow
cytometri
buffer
pb
invitrogen
contain
bsa
sodium
azid
sigmaaldrich
stain
appropri
pretitr
flow
cytometri
antibodi
cell
sometim
fix
use
biolegend
fix
buffer
acquir
bd
facscanto
ii
instrument
analys
use
flowjo
softwar
assess
phosphoryl
residu
cell
instead
mildli
fix
fix
buffer
permeabilis
commerci
methanol
buffer
truepho
buffer
biolegend
hour
stain
describ
intracellular
cytokin
stain
cell
fix
fix
buffer
follow
permeabilis
flow
cytometri
buffer
contain
saponin
sigmaaldrich
compens
perform
use
ebiosci
ultracomp
bead
accord
manufactur
instruct
antibodi
use
violet
violet
violet
mhc
class
ii
brilliant
violet
fluor
antibodi
purchas
biolegend
uk
unless
otherwis
specifi
cytokin
level
supernat
measur
use
ebiosci
readysetgo
elisa
kit
accord
manufactur
instruct
plate
read
nm
plate
reader
experi
statist
test
perform
microsoft
excel
graphpad
prism
softwar
use
averag
technic
replic
possibl
statist
test
posttest
detail
relev
figur
legend
p
valu
less
consid
signific
dc
macrophag
critic
initi
adapt
immun
bcg
induc
upregul
express
pulmonari
dc
howev
unclear
whether
hold
true
macrophag
dc
macrophag
therefor
infect
bcg
rang
multipl
infect
moi
across
two
timepoint
h
h
surfac
express
assess
flow
cytometri
shown
fig
posit
control
lipopolysaccharid
lp
abl
significantli
increas
express
cell
type
p
strike
fold
increas
macrophag
h
upon
infect
bcg
apc
type
express
high
level
compar
unstimul
control
h
h
p
dose
trend
observ
increas
moi
macrophag
h
next
transgen
strain
bcg
express
green
fluoresc
protein
gfp
use
determin
whether
upregul
depend
direct
interact
apc
bacteria
cell
gate
gfp
fluoresc
gfpneg
ie
bystand
gfppo
ie
infect
popul
test
express
anticip
gfppo
infect
cell
display
increas
express
proportion
infecti
dose
fig
surprisingli
howev
gfpneg
bystand
cell
also
exhibit
similar
dosedepend
increas
express
gfppo
cell
significantli
upregul
compar
uninfect
control
highest
moi
p
approxim
directli
infect
cell
support
observ
filtrat
bcg
infect
supernat
appli
new
cell
abl
upregul
supplementari
fig
expect
control
supernat
uninfect
cell
affect
express
data
strongli
suggest
solubl
secret
factor
cultur
drive
upregul
bcg
interestingli
bcg
abl
upregul
member
famili
certain
degre
pattern
skew
upregul
compar
supplementari
fig
murin
gene
control
complex
regulatori
network
induc
number
inflammatori
cytokin
tlr
mani
control
mechan
cell
typespecif
sinc
mycobacteria
adept
drive
sinc
capabl
bind
promot
tolerogen
hypothesis
signal
pathway
mediat
observ
effect
infect
dc
macrophag
infect
h
intracellular
flow
cytometri
use
determin
level
tyrosin
residu
phosphoryl
observ
fig
bcg
abl
hyperphosphoryl
transcript
factor
compar
unstimul
cell
p
notabl
trend
increas
phosphoryl
compar
bcg
posit
control
lp
next
hypothesis
apc
produc
cytokin
activ
weakli
strongli
prototyp
myeloidtyp
cytokin
apc
therefor
infect
bcg
stimul
lp
h
level
measur
elisa
bcg
found
induc
potent
quantiti
dc
macrophag
rang
moi
fig
p
bcg
vs
unstimul
cell
bcg
elicit
cell
type
strikingli
regard
product
bcg
greatli
surpass
abil
lp
moi
concentr
cytokin
compar
posit
control
hypothesi
bcg
induc
cytokin
upregul
treat
dc
macrophag
differ
concentr
measur
upregul
flow
cytometri
dc
fig
play
domin
role
upregul
express
compar
cytokin
use
combin
margin
increas
level
express
confer
macrophag
contrast
behav
similarli
term
receptor
upregul
combinatori
effect
clearli
evid
pgml
cell
type
dosedepend
effect
pgml
cytokin
combin
superior
pgml
upregul
express
next
macrophag
infect
bcg
h
cell
permeabilis
costain
cell
divid
popul
level
quantifi
shown
fig
cell
exhibit
significantli
lower
level
phosphoryl
compar
counterpart
p
doubl
fluoresc
intens
experi
taken
togeth
data
suggest
bcg
utilis
interleukin
signal
pathway
order
upregul
express
next
question
whether
direct
intervent
axi
could
revert
upregul
bcg
end
employ
combin
monoclon
antibodi
mab
known
block
cytokin
receptor
alongsid
pharmacolog
inhibitor
stattic
wellcharacteris
highli
specif
smallmolecul
inhibitor
transcript
test
whether
neutralis
biolog
activ
endogen
cytokin
could
reduc
increas
express
caus
bcg
cell
first
preincub
mab
mab
blockad
combin
h
isotyp
control
serv
control
nonspecif
activ
cell
infect
bcg
h
express
determin
fig
blockad
significantli
reduc
express
p
compar
isotyp
control
baselin
expect
combin
block
receptor
led
greatest
reduct
fluoresc
p
vs
isotyp
control
keep
hypothesis
role
bcginduc
express
blockad
receptor
also
led
larg
reduct
phosphoryl
shown
fig
bcg
isotyp
mfi
bcg
dual
blockad
mfi
confirm
mediat
upregul
express
bcg
cell
pretreat
stattic
vehicl
control
hour
infect
low
dose
bacteria
fig
lp
serv
posit
control
sinc
induc
express
via
hour
cell
treat
stattic
infect
bcg
show
dramat
reduc
express
level
compar
treat
vehicl
control
p
reduct
express
similar
result
observ
lp
strikingli
rest
cell
treat
stattic
actual
increas
express
compar
vehicl
control
although
nonsignific
trend
high
variat
collect
data
prove
bcg
could
modul
express
signal
circuit
proofofprincipl
vivo
immunogen
assay
next
perform
order
establish
target
receptor
bcg
immunis
could
lead
increas
tcell
function
cytokin
panel
span
sever
hallmark
cytokin
use
determin
tcell
reactogen
vaccin
model
recal
mycobacteri
antigen
fig
first
upregul
vivo
determin
subcutan
immunis
bcg
follow
characteris
express
drain
lymph
node
supplementari
fig
found
bcg
abl
upregul
mhc
class
iihigh
dc
unabl
tcell
confirm
specif
effect
apc
next
mice
treat
mg
block
antibodi
via
intraperiton
rout
follow
immunis
subcutan
bcg
mice
given
followup
booster
immunis
maintain
blockad
isotyp
control
use
concentr
control
nonspecif
effect
day
splenocyt
immunis
mice
puls
either
immunodomin
latencyassoci
antigen
acr
respect
mixtur
protein
antigen
ppd
shown
fig
gener
trend
increas
antigenspecif
cytokin
product
tcell
blockad
bcg
induc
significantli
respons
ppd
p
compar
isotyp
control
product
also
increas
respons
p
regard
nonsignific
increas
caus
blockad
antigen
recal
condit
turn
attent
tcell
compart
fig
found
bcg
much
poorer
induc
antigenspecif
cytokin
respons
observ
previous
except
puls
p
splenocyt
mice
receiv
bcg
isotyp
control
unabl
produc
cytokin
splenocyt
mockimmunis
mice
two
cytokin
found
increas
blockad
beyond
pb
control
group
respons
ppd
p
p
howev
effect
margin
thu
conclud
blockad
effect
boost
tcell
immun
margin
effect
boost
tcell
respons
longrecognis
bacteria
inde
pathogen
belong
genet
distinct
phyla
capabl
modul
repertoir
costimulatori
coinhibitori
molecul
express
apc
thu
affirm
critic
import
said
receptor
direct
adapt
immun
respons
mycobacteria
repres
exampl
immun
evas
par
excel
due
ancient
histori
coevolut
mammalian
immun
inde
virtual
pathogen
mycobacteria
oblig
parasit
requir
intracellular
resourc
order
thrive
propag
therefor
surpris
biolog
equip
effect
counter
adapt
immun
respons
would
lead
clearanc
central
import
molecul
control
tcell
immun
mice
infect
mycobacteria
harbour
pulmonari
dc
express
high
level
restrict
antigen
present
blockad
blood
lung
lavag
tb
patient
enhanc
respons
mtb
antigen
seen
greater
cytokin
product
tcell
furthermor
blockad
abl
rescu
cell
function
exhaust
demonstr
revers
tcell
bladder
cancer
tumour
surfac
reportedli
decor
high
level
molecul
tumourinfiltr
b
tcell
express
high
level
utilis
bcg
prophylact
tb
therapeut
malign
treatment
diseas
combin
strategi
mitig
effect
could
provid
strong
advantag
efficaci
bcg
studi
first
time
shown
bcg
drive
upregul
express
apc
autocrineparacrin
cytokin
circuit
lead
phosphoryl
upregul
coinhibitori
receptor
illustr
fig
known
time
bcg
strong
induc
cytokin
via
rudimentari
tlr
signal
howev
known
drive
express
biphas
respons
observ
inhibit
lead
decreas
express
rest
instead
nonsignific
increas
consist
notion
gene
promot
requir
distinct
transcript
apparatu
steadyst
activ
infect
accord
fact
dc
macrophag
display
moder
level
constitut
express
absenc
appreci
cytokin
physiolog
undoubtedli
prevent
spontan
activ
adapt
immun
system
use
mab
abl
neutralis
receptor
vivo
augment
quantiti
cytokin
produc
tcell
respons
recal
antigen
proofofprincipl
experi
interest
note
blockad
vivo
greatli
boost
antigenspecif
tcell
respons
beyond
mockimmunis
control
group
bcg
wide
known
minim
induc
cytotox
tcell
respons
strong
bia
toward
may
due
socal
decoy
antigen
serv
divert
respons
away
immunogen
epitop
cytotox
whether
enhanc
tcell
immunogen
absenc
strong
tcell
immunogen
lead
better
vaccin
ie
case
tb
immunotherapeut
ie
case
carcinoma
outcom
warrant
test
diseasespecif
anim
model
import
limit
studi
unlik
constitut
two
cytokin
drive
pathway
expect
redund
cytokin
drive
long
adequ
activ
also
activ
nearli
member
cytokin
famili
howev
two
abund
cytokin
secret
myeloid
cell
upon
activ
dual
blockad
receptor
led
reduct
could
reflect
fact
block
antibodi
complet
neutralis
biolog
also
weakli
activ
tlr
signal
srcfamili
exclud
possibl
contribut
phosphoryl
state
furthermor
undoubtedli
transcript
cofactor
recruit
promot
alongsid
regardless
conclus
shown
biolog
essenti
activ
bcg
link
biolog
target
amen
intervent
clinic
set
eg
tocilizumab
mab
inde
studi
provid
four
point
intervent
use
bcg
cytokin
ii
cytokin
receptor
iii
transcript
factor
iv
receptor
present
highli
appeal
therapeut
target
role
express
due
fact
pleiotrop
master
control
gener
toler
apc
suppress
nitric
oxid
costimulatori
molecul
given
new
find
target
pathway
vaccin
bcg
tb
malign
could
reap
multipl
therapeut
benefit
conclus
reveal
novel
molecular
insight
bcg
upregul
apc
allow
improv
immunogen
specif
antigen
also
intric
understand
fundament
hostpathogen
interact
futur
work
focu
explor
pathway
specif
diseas
model
reli
bcg
treatment
aim
bolster
immunolog
paramet
ultim
treatment
efficaci
